Gabriel de Camargo Zaccariotto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gabriel de Camargo Zaccariotto has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Angelica Maria Mazuera Zapata
Nanomedicine and Nanotoxicology Group, São Carlos Institute of Physics
1 shared publication- Camila Fernanda Rodero
Sao Paulo State University
1 shared publication Fernanda Coelho
Nanomedicine and Nanotoxicology Group, São Carlos Institute of Physics
1 shared publicationJoão Victor Brandão Quitiba
Nanomedicine and Nanotoxicology Group, São Carlos Institute of Physics
1 shared publication- Lorena Leticia Peixoto de Lima
Nanomedicine and Nanotoxicology Group, São Carlos Institute of Physics
1 shared publication Maria Julia Bistaffa
Nanomedicine and Nanotoxicology Group, São Carlos Institute of Physics
1 shared publication
Latest Publications
- Open Access
- 1 June 2026
- Published by Elsevier in Biotechnology Advances
- Vol. 91, 108942
CAR-T cells and cancer nanovaccines: Comparative insights into advances and translational challenges
- 1 June 2026
- Published by Elsevier in Biotechnology Advances
- Vol. 91, 108942
Open AccessCAR-T cells and cancer nanovaccines: Comparative insights into advances and translational challenges
- Open Access
- 9 April 2025
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 19 (17) , 16204-16223
Cancer Nanovaccines: Mechanisms, Design Principles, and Clinical Translation
Cancer immunotherapy has transformed the landscape of oncological treatment by employing various strategies to teach the immune system to eliminate tumors. Among these, cancer nanovaccines are an emerging strategy that utilizes nanotechnology to enhance immune activation in response to tumor antigens. This review addresses the principles behind the different technologies in this field aimed at generating a robust and effective immune response. The diversity of strategies adopted for the design of nanovaccines is discussed, including the types of active agents, nanocarriers, their functionalizations, and the incorporation of adjuvants. Furthermore, strategies to optimize nanoparticle formulations to enhance the antigen presentation, target immune cells, and organs and promote strong and durable antitumor responses are explored. Finally, we analyze the current state of clinical application, highlighting ongoing clinical trials and the future potential of cancer nanovaccines. The insights presented in this review aim to guide future research and development efforts in the field, contributing to the advancement of more effective and targeted nanovaccines in the fight against cancer.
- 9 April 2025
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 19 (17) , 16204-16223
Open AccessCancer Nanovaccines: Mechanisms, Design Principles, and Clinical Translation
Cancer immunotherapy has transformed the landscape of oncological treatment by employing various strategies to teach the immune system to eliminate tumors. Among these, cancer nanovaccines are an emerging strategy that utilizes nanotechnology to enhance immune activation in response to tumor antigens. This review addresses the principles behind the different technologies in this field aimed at generating a robust and effective immune response. The diversity of strategies adopted for the design of nanovaccines is discussed, including the types of active agents, nanocarriers, their functionalizations, and the incorporation of adjuvants. Furthermore, strategies to optimize nanoparticle formulations to enhance the antigen presentation, target immune cells, and organs and promote strong and durable antitumor responses are explored. Finally, we analyze the current state of clinical application, highlighting ongoing clinical trials and the future potential of cancer nanovaccines. The insights presented in this review aim to guide future research and development efforts in the field, contributing to the advancement of more effective and targeted nanovaccines in the fight against cancer.